Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 08:00 ET | Source: Lixte Biotechnology Holdings, Inc.

Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

-Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE) --...
April 09, 2026 08:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer.
April 09, 2026 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) --...
April 09, 2026 02:00 ET | Source: Trogenix

Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain...
April 09, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,...
April 09, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,...
April 08, 2026 11:03 ET | Source: Trogenix

Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour recurrence in a brain...
April 08, 2026 10:00 ET | Source: Steadman Philippon Research Institute

Steadman Philippon Research Institute and Hospital for Special Surgery to Host Vail Hip Summit April 9–11 at Four Seasons Resort Vail

Vail, Colorado, April 08, 2026 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI), in collaboration with New York-based Hospital for Special Surgery (HSS) and with support from Vail...
April 08, 2026 09:01 ET | Source: iHerb Holdings, Inc.

iHerb Named Exclusive International Retailer for Kylie Jenner’s k2o

iHerb today announced an exclusive international partnership with k2o, a new hydration and beauty drink, founded by Kylie Jenner.
April 08, 2026 07:00 ET | Source: Incyclix Bio

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...